Status:
COMPLETED
A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants
Lead Sponsor:
Eli Lilly and Company
Collaborating Sponsors:
Loxo Oncology, Inc.
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The main purpose of study is to compare different formulations of LY3410738 under fasting condition by looking at the amount of the study drug, LY3410738, that gets into the blood stream and how long ...
Eligibility Criteria
Inclusion
- Must have Body mass index (BMI) within the range of 18.0 to 32.0 kilograms per square meter (kg/m\^2), inclusive.
- Male and female participants in good health, determined by no clinically significant findings from medical history, 12-lead Electrocardiogram (ECG), vital sign measurements, or clinical laboratory evaluations as assessed by the investigator.
- Female participants of non-childbearing potential and male participants who follow standard contraceptive methods.
- Must have comply with all study procedures, including the 3-night stay at the Clinical Research Unit (CRU) and follow-up phone call.
Exclusion
- History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor.
- Positive serologic test for hepatitis B surface antigen (HBsAg), hepatitis B virus immunoglobulin M (HBV IgM) core antibody, hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody at Screening.
- Positive polymerase chain reaction (PCR) test for COVID-19 at Screening.
- Known ongoing alcohol and/or drug abuse within 2 years prior to Screening.
- History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
- Have previously received LY3410738 in any other study investigating LY3410738, within 30 days prior to Day 1.
- Have history of a major surgical procedure within 30 days prior to Screening.
Key Trial Info
Start Date :
October 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 28 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06181084
Start Date
October 11 2021
End Date
April 28 2022
Last Update
December 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Labcorp Clinical Research
Daytona Beach, Florida, United States, 32117